Bruker

Areas like pharma and food and water testing could prove growth areas for the platform as instrument sales growth slows in the clinic microbiology space.

The company reported revenues of $414.9 million as acquisitions boosted revenues 6 percent and foreign exchange rates lowered them by 2 percent.

The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.

The new version of the mass spectrometry-based system adds 144 microbial species to its database and includes new tools for sample preparation.

While actual clinical implementation remains distant, MALDI imaging technology has advanced to the point where it might feasibly be applied to pathology.

With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.

The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.

The deal gives BD global distribution rights for several Bruker MALDI Biotyper products, expanding a 2010 agreement key to both firms' microbiology businesses.

The company reported total revenues of $384.9 million, up from $375.4 million for the first quarter of 2016 and above analysts' consensus estimate of $372.7 million.

Presented this week at the ECCMID annual meeting, the method uses mass spec to detect alterations to bacteria lipopolysaccharides that confer resistance.

Pages

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.